deferoxamine has been researched along with papaverine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bassenge, E; Pohl, U; Stewart, DJ | 1 |
| Attali, JR; Ledoux, S; Nitenberg, A; Paycha, F; Sachs, R; Valensi, P | 1 |
1 review(s) available for deferoxamine and papaverine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for deferoxamine and papaverine
| Article | Year |
|---|---|
Free radicals inhibit endothelium-dependent dilation in the coronary resistance bed.
Topics: Acetylcholine; Adenosine; Animals; Catalase; Coronary Vessels; Deferoxamine; Electrolysis; Endothelium, Vascular; Female; Free Radicals; In Vitro Techniques; Kinetics; Male; Muscle, Smooth, Vascular; Papaverine; Perfusion; Rabbits; Serotonin; Superoxide Dismutase; Vasodilation | 1988 |
Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors.
Topics: Adult; Antidotes; Arginine; Cold Temperature; Coronary Angiography; Coronary Vessels; Deferoxamine; Diabetes Mellitus, Type 2; Female; Hemodynamics; Humans; Iron Chelating Agents; Male; Middle Aged; Papaverine; Risk Factors; Stress, Physiological; Vasodilator Agents; Vasomotor System | 1998 |